• Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Top Trading Strategy
No Result
View All Result
Home Breaking News

Emergent Biosolutions shares plunge more than 37% after U.S. cancels deal with Covid vaccine maker

by
November 5, 2021
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Related Posts

At least 21 are dead after tornadoes rake the U.S. Midwest and South

NBA and players reach a deal for a new 7-year labor agreement

D.E. Shaw spots an opportunity to boost margins at FleetCor – and do so amicably

On the cusp of record inflows? Playing the hot international trade with ETFs

Test tubes are seen in front of a displayed Emergent logo in this illustration taken, May 21, 2021.

Dado Ruvic | Reuters

Emergent Biosolutions shares plunged 37% Friday after the company disclosed to investors that the federal government had canceled its multimillion-dollar contract with the Covid-19 vaccine manufacturer.

Emergent, the Maryland-based company blamed in March for ruining millions of Johnson & Johnson‘s Covid doses after the shots were contaminated with ingredients intended for the AstraZeneca vaccine, was awarded a $628 million U.S. government contract to help make the shots last year.

An inspection by the Food and Drug Administration later found its plant in Baltimore was unsanitary and unsuitable to manufacture the shots. In a 13-page report, inspectors wrote that the facility used to manufacture the vaccine was “not maintained in a clean and sanitary condition” and was “not of suitable size, design, and location to facilitate cleaning, maintenance, and proper operations.” The U.S. would put J&J in charge of the plant and end the production of the AstraZeneca vaccine at the facility.

The company will forgo $180 million due to the contract’s termination, executives told investors on a call Thursday, according to a transcript by FactSet.

It also said it will continue working with J&J to produce its vaccines at the Baltimore plant as its deal with the company is separate from its contract with the federal government. As of late September, Emergent has contributed “over 100 million dose equivalents of Covid vaccine” for global distribution, the company told investors.

The work “we accomplished under the program and related task order contracts with the U.S. government served a critically important purpose,” Emergent CEO Robert Kramer said on the call, “one that our entire organization is immensely proud of.”

When he testified before a House committee in May, Kramer expressed disappointment that conditions at the plant caused the doses to become contaminated and required them to suspend manufacturing.

Emergent spokesman Matt Hartwig told CNBC on Friday that the company and the federal government “mutually agreed upon final payments to close out all open task orders and end the base CIADM contract.

“These are mutually agreed upon terminations for convenience and neither party is alleging breach of default by the other,” he added.

Next Post

1st Look at Local Housing Markets in October

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Breaking News

NBA and players reach a deal for a new 7-year labor agreement

by
April 1, 2023
0

NBA Commissioner Adam Silver speaks to the media during a press conference as part of the 2022 All-Star Weekend at...

Read more

NBA and players reach a deal for a new 7-year labor agreement

At least 21 are dead after tornadoes rake the U.S. Midwest and South

D.E. Shaw spots an opportunity to boost margins at FleetCor – and do so amicably

On the cusp of record inflows? Playing the hot international trade with ETFs

ETF outlook: Why Wall Street strategists aren’t chasing a growth stock trade just yet

Markets and the economy survived a tough first quarter, but it’s not going to get any easier

Load More

All rights reserved by www.toptradingstrategy.net

  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.